Voting Results of 2026 Annual General Meeting
At Legend Biotech Corporation’s (the “Company”) annual general meeting of shareholders held on September 24, 2026 (the “AGM”), the Company’s shareholders:
| · | received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2025; |
| · | ratified the appointment of Ernst & Young LLP as the Company’s independent auditor for the fiscal year ending December 31, 2026; |
| · | re-elected each of Mr. Robin Meng, Dr. Corazon D. Sanders, Dr. Li Mao and Dr. Peter Salovey to serve as a Class III director for a three-year term; |
| · | approved the amendment and restatement of the Company’s 2020 Restricted Shares Plan to increase the aggregate number of ordinary shares reserved for issuance by 19,100,000 ordinary shares; and |
| · | authorized each of the directors and officers of the Company to take any and every action that might be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit. |
A total of approximately 330,199,682 ordinary shares, including those underlying ADSs, representing approximately 84.9% of the 388,976,826 ordinary shares issued and outstanding as of August 17, 2026, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:
| For | Against | Abstain | ||||||||||||||||||||||
| Resolutions | Votes | % | Votes | % | Votes | % | ||||||||||||||||||
| Reception of Audited Financial Statements | 329,998,122 | 84.837 | % | 110,480 | 0.028 | % | 91,080 | 0.023 | % | |||||||||||||||
| Ratification of appointment of Ernst & Young LLP as Independent Auditor for Fiscal Year 2026 | 329,955,758 | 84.827 | % | 144,190 | 0.037 | % | 99,734 | 0.026 | % | |||||||||||||||
| Election of Directors | ||||||||||||||||||||||||
| Mr. Robin Meng (Class III) | 273,381,862 | 70.282 | % | 56,768,390 | 14.594 | % | 49,430 | 0.013 | % | |||||||||||||||
| Dr. Corazon D. Sanders (Class III) | 326,472,036 | 83.931 | % | 3,681,710 | 0.947 | % | 45,936 | 0.012 | % | |||||||||||||||
| Dr. Li Mao (Class III) | 328,120,942 | 84.355 | % | 1,999,436 | 0.514 | % | 79,304 | 0.020 | % | |||||||||||||||
| Dr. Peter Salovey (Class III) | 328,187,592 | 84.372 | % | 1,967,750 | 0.506 | % | 44,340 | 0.011 | % | |||||||||||||||
| Amendment and Restatement of 2020 Restricted Shares Plan | 279,130,008 | 71.760 | % | 20,732,988 | 5.330 | % | 30,336,686 | 7.799 | % | |||||||||||||||
| Authorization of Directors and Officers | 328,624,268 | 84.484 | % | 1,441,908 | 0.371 | % | 133,506 | 0.034 | % | |||||||||||||||